According to Haizheng Pharmaceutical's announcement, net profit attributable to shareholders of listed companies for the first half year of 2026 is expected to be 600 million yuan to 650 million yuan, an increase of 100.62% to 117.34% year on year; after deducting non-net profit of 490 million yuan to 530 million yuan, an increase of 52.54% to 64.99% year on year. The pre-increase in performance was mainly due to the steady operation of various core business segments, increased sales of innovative drugs and other products, lower production costs, product structure optimization; and the transfer of 100% of Zhejiang Pharmaceutical Industry Co., Ltd.'s shares to foreign countries, and non-recurring profits and losses increased year-on-year.

According to Haizheng Pharmaceutical's announcement, net profit attributable to shareholders of listed companies for the first half year of 2026 is expected to be 600 million yuan to 650 million yuan, an increase of 100.62% to 117.34% year on year; after deducting non-net profit of 490 million yuan to 530 million yuan, an increase of 52.54% to 64.99% year on year. The pre-increase in performance was mainly due to the steady operation of various core business segments, increased sales of innovative drugs and other products, lower production costs, product structure optimization; and the transfer of 100% of Zhejiang Pharmaceutical Industry Co., Ltd.'s shares to foreign countries, and non-recurring profits and losses increased year-on-year.